石药集团：5-HT2A受体激动剂在美国获临床试验批准

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) for its Class 1 chemical drug, a selective 5-HT2A receptor agonist, to conduct clinical trials in the United States [1] Group 1 - The selective 5-HT2A receptor agonist is designed to improve the condition of patients with depressive disorders [1] - The drug shows rapid onset of action with a single dose and has a long-lasting effect without causing hallucinogenic risks [1] - The product has also been approved by the National Medical Products Administration (NMPA) of China to conduct clinical trials in China starting from November 2025 [1]